This is a great video. Dr. Seth Baum's Interventional prevention video
It is a scientific version of my 2010 video on how to prevent heart disease
This is a tremendous validation of the Tubby Theory from Topeka that I wrote in 2009 published in 2010.
I used Dr. Seth's metrics for the last four years to prove that a 60% fat diet does not make cause tremendous plaque build up.
I have not seen detailed follow up CIMT's in any other diet case.
Canadian update on risk stratification
Even when a family history of premature CVD is taken into account, there is often ambiguity about the need for statin therapy for patients with a 10 year FRS of 5-19% and LDL C < 3.5mmol/l (135 mg/dl).
Current Canadian dyslipidemia guidelines recommend consideration of a diversity of other factors, including biochemical measurements and imaging studies to help determine whether the calculated FRS may be misleadingly low and whether statin therapy might, therefore, be prudent.
However, efficient utilization of the plethora of secondary factors makes this decision process itself potentially ambiguous.
This brief summary provides a practical approach for utilizing clinical information, basic biochemical tests and more specialized test, such as carotid ultrasound and coronary artery calcium scoring to identify groups of patients at higher risk for ASCVD than suggested by FRS.
Identification of patients at increased risk of ASCVD yet with an intermediate Framingham risk score (FRS) of 5-19% is enhanced by considering other medical issues and by secondary testing.
A structured approach to the evaluation of intermediate FRS patients is presented. Using such a strategy it is likely more patients who will benefit from statin therapy will be initiated on treatment.
Canadian update on risk stratification
Abstract
Decisions for statin therapy in the primary prevention of atherosclerotic cardiovascular disease (ASCVD) are generally made using the 10-year Framingham risk score (FRS).Even when a family history of premature CVD is taken into account, there is often ambiguity about the need for statin therapy for patients with a 10 year FRS of 5-19% and LDL C < 3.5mmol/l (135 mg/dl).
Current Canadian dyslipidemia guidelines recommend consideration of a diversity of other factors, including biochemical measurements and imaging studies to help determine whether the calculated FRS may be misleadingly low and whether statin therapy might, therefore, be prudent.
However, efficient utilization of the plethora of secondary factors makes this decision process itself potentially ambiguous.
This brief summary provides a practical approach for utilizing clinical information, basic biochemical tests and more specialized test, such as carotid ultrasound and coronary artery calcium scoring to identify groups of patients at higher risk for ASCVD than suggested by FRS.
Identification of patients at increased risk of ASCVD yet with an intermediate Framingham risk score (FRS) of 5-19% is enhanced by considering other medical issues and by secondary testing.
A structured approach to the evaluation of intermediate FRS patients is presented. Using such a strategy it is likely more patients who will benefit from statin therapy will be initiated on treatment.
No comments:
Post a Comment